L1CAM and cancer: At the Center for Radiopharmaceutical Sciences of the Paul Scherrer Institute we developed the anti-L1 cell adhesion molecule (L1CAM) chimeric monoclonal antibody chCE7 for radioimmunotherapeutic (RIT) approaches to cancer.